RESUMEN

Chronic pruritus is a common condition that has a detrimental impact on quality of life. As the molecular pathogenesis of itch is elucidated, novel therapies that disrupt itch pathways are being investigated. Emerging treatments include drugs targeting the neural system, drugs targeting the immune system, antihistamines, bile acid transport inhibitors, and topical drugs that work through a variety of mechanisms such as phosphodiesterase-4 inhibition or targeting of nerve ion channels. Many of these therapies show promising results in the treatment of chronic itch of various etiologies, such as atopic dermatitis, psoriasis, uremic pruritus, and cholestatic pruritus.

Asunto(s)

Antipruriginosos/uso terapéutico , Interleucinas/antagonistas & inhibidores , Antagonistas del Receptor de Neuroquinina-1/uso terapéutico , Prurito/tratamiento farmacológico , Toxinas Botulínicas Tipo A/uso terapéutico , Cannabinoides/uso terapéutico , Enfermedad Crónica , Descubrimiento de Drogas , Antagonistas de los Receptores Histamínicos/uso terapéutico , Humanos , Inhibidores de las Cinasas Janus/uso terapéutico , Antagonistas de Leucotrieno/uso terapéutico , Inhibidores de Fosfodiesterasa/uso terapéutico , Receptor trkA/antagonistas & inhibidores , Receptores Opioides/agonistas , Canales Catiónicos TRPV/antagonistas & inhibidores